Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel:...

مرکز و کتابخانه مطالعات اسلامی به زبان های اروپایی

منو

" Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors "
Shakhbazova, Anastasia; Hinds, Brian; Marsch, Amanda F

Document Type	:	AL
Record Number	:	923156
Doc. No	:	LA7nf6c8hc
Language of Document	:	English
Main Entry	:	Shakhbazova, Anastasia; Hinds, Brian; Marsch, Amanda F
Title & Author	:	Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors [Article]\ Shakhbazova, Anastasia; Hinds, Brian; Marsch, Amanda F
Title of Periodical	:	Dermatology Online Journal
Volume/ Issue Number	:	26/3
Date	:	2020
Abstract	:	Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inherited or may occur sporadically with multiple red-brown, thin plaques in a photodistribution. The condition more often affects middle-aged women and is often recalcitrant to therapy. In rare literature reports, systemic medications can trigger exacerbation or promote inflammation in pre-existing lesions of DSAP. We present a novel case of chemotherapy-associated DSAP inflammation in a 66-year-old woman after triple therapy with durvalumab (PD-L1 inhibitor), olaparib (PARP inhibitor) and paclitaxel, showing similarities to primary lichen planus-like eruption from immune checkpoint inhibitors.